Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
In resected intrahepatic cholangiocarcinoma with an R0 margin <1 mm and perineural invasion, would you consider adjuvant RT in addition to capecitabine?
Related Questions
What would be your radiotherapy plan for an overall stage IIA, low-lying, MMRd rectal adenocarcinoma to try to avoid APR?
For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative dose for more durable control?
What's your follow-up protocol for a near complete response (nCR) in rectal patients considering non-operative management (NOM)?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
In a young patient with stage IIIB, low lying rectal cancer who is s/p 8 cycles of FOLFOX, do you prefer short or long course radiation prior to surgery?
Which GI cancer patients do you use oral contrast in staging CT scans?
Would you hold HAI/ FUDR for SBRT of a residual liver metastasis following hepatic metastasectomy?
Are the results of CONKO-007 changing practice for the management of pancreatic cancer?
If a patient with initially borderline resectable pancreatic cancer receives neoadjuvant CHT followed by CRT and is ultimately deemed unresectable, do you consider an RT boost?
